Our findings provide evidence to suggest that GLI2 rearrangements are likely drivers of SSTs and may serve as potential ancillary markers for the diagnosis of these tumors, and that GLI2 should be included in panels surveying fusion genes in human cancers. The gene discussed is GLI2; the disease is cancer.